Under the agreement, Antares will apply its advanced transdermal delivery (ATD) gel platform to create a new, branded pharmaceutical product. Antares will recognize R&D revenue from this work, which is currently underway. Commercial terms have been agreed upon and will be included in a subsequent license agreement upon successful completion of the initial phase of this program.
“This agreement represents another key application of our ATD platform further validating both the system and our overall product based strategy,” said Jack Stover, president and CEO of Antares.
Antares’ patent-protected ATD gel technology platform has been clinically and commercially validated for the systemic delivery of a variety of compounds. In addition, modified gel systems for non-systemic, dermal delivery have also been developed.